RaySearch Laboratories AB announces today that three new software solutions from the collaboration with Varian Medical Systems (NYSE: VAR) have been launched. The products are integrated as modules in the latest release of Varian’s Eclipse™ treatment planning system, which recently received 510(k) clearance from the FDA. The products are treatment planning software modules for optimization of conventional three-dimensional conformal radiation therapy (3D-CRT), radiobiological evaluation and radiobiological optimization. 3D-CRT is a well established technique that comprises the bulk of all radiation treatments. However, treatment planning for 3D-CRT can be a complex time-consuming process. The user of the software must iteratively vary treatment parameters manually until a satisfactory result is attained in terms of dose to the tumor and optimal normal tissue sparing. The process can take several hours. The new conformal optimization module uses advanced algorithms to automate this process. The software optimizes all relevant treatment parameters to determine the best possible solution in a matter of minutes. This saves considerable time and also has the potential to significantly improve treatment quality. The other two modules for radiobiological evaluation and optimization employ models to predict how tumors and healthy tissue will react when irradiated. The radiobiological evaluation tool makes it possible to evaluate the probability that a tumor can be controlled and the risk of damaging healthy tissue, for a given treatment plan. Clinicians can use this information to make decisions about how to adapt the treatment plan for the best possible outcomes, and make changes in the event that treatment sessions have to be postponed. The biological optimization product allows clinicians to formulate treatment objectives directly in clinical terms, such as the desired probability of controlling the tumor or the risk of causing radiation-induced complications. This is a highly useful complement to traditional techniques based on physical dose that do not take biological response into account. “These new tools will assist clinicians in achieving optimum treatment plans and save a lot of time in dosimetry,” said Jeff Amacker, director of clinical solutions for Varian. “It’s another step toward improving both the quality and cost effectiveness of radiation oncology.” “Varian is the largest player in the radiation therapy industry so of course this product launch is a major event in RaySearch’s history,” says Johan Löf, CEO of RaySearch. “These are highly useful products, offering Eclipse users several tools for automating and enhancing everyday treatment planning operations at their clinics. There are good grounds to believe that these products will be of significant commercial importance to RaySearch when Varian starts rolling out the products later this summer,” concludes Johan Löf. ABOUT RAYSEARCH RaySearch Laboratories is a medical-technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are sold through license agreements with leading partners such as Philips, Varian, Siemens, Nucletron, IBA Dosimetry and TomoTherapy. Thirteen products have been launched to date and RaySearch’s software is used at some 1,500 clinics in more than 30 countries. In addition, existing license agreements cover more than 15 other products that are scheduled to be launched in the coming years. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on the OMX Nordic Exchange Stockholm. For more information about RaySearch, visit www.raysearchlabs.com. FOR FURTHER INFORMATION, CONTACT: Johan Löf, President and CEO, RaySearch Laboratories AB Telephone: +46 (0)8-545 061 30 johan.lof@raysearchlabs.com
Press releases
